A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100actual
Sites
10
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-30 | actual | When the study began enrolling |
| Primary completion | 2025-10-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-18 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Postmenopausal Osteoporosis
Intervention
- Drug: Romosozumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAE)
measured Up to 12 months
Number of Participants Experiencing Treatment-emergent Serious Adverse Events (TESAE)
measured Up to 12 months
Number of Participants Experiencing Clinically Significant Changes in Laboratory Assessments
measured Baseline, Month 12
Number of Participants With Clinically Significant Changes in Vital Signs
measured Baseline, Month 12
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed